Alpine Income Property Trust, Inc. (PINE) Market Cap
Alpine Income Property Trust, Inc. has a market capitalization of $275.5M.
Financials based on reported quarter end 2025-12-31
Price: $19.23
▼ -0.23 (-1.18%)
Market Cap: 275.51M
NYSE · time unavailable
CEO: John Albright
Sector: Real Estate
Industry: REIT - Retail
IPO Date: 2019-11-22
Website: https://www.alpinereit.com
Alpine Income Property Trust, Inc. (PINE) - Company Information
Market Cap: 275.51M · Sector: Real Estate
Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that acquires, owns and operates a portfolio of high-quality single-tenant net leased commercial income properties.
Analyst Sentiment
Based on 12 ratings
Analyst 1Y Forecast: $19.38
Average target (based on 3 sources)
Consensus Price Target
Low
$20
Median
$20
High
$21
Average
$20
Potential Upside: 5.3%
Price & Moving Averages
Related Companies in Real Estate
BRT APARTMENTS CORP (BRT)
Real Estate
$0.27B
Mkt Cap
CITY OFFICE REIT INC (CIO)
Real Estate
$0.28B
Mkt Cap
SITE CENTERS CORP (SITC)
Real Estate
$0.28B
Mkt Cap
SEAPORT ENTERTAINMENT GROUP INC (SEG)
Real Estate
$0.28B
Mkt Cap
ARES COMMERCIAL REAL ESTATE REIT C (ACRE)
Real Estate
$0.29B
Mkt Cap
SERVICE PROPERTIES TRUST (SVC)
Real Estate
$0.26B
Mkt Cap
Fundamentals Overview
Management is upbeat on growth—Q4 AFFO per common share +22.7% and record 2025 investments ($277.7M) with strong balance-sheet metrics (net debt/EBITDA improved to 6.7x, pricing improved 10–15 bps on refinanced debt). The tone in prepared remarks is confident about 2026 guidance ($2.07–$2.11 FFO; $2.09–$2.13 AFFO) and a continued 20% target loan allocation. However, the Q&A reveals operational hurdles that temper optimism: Walgreens is not fully resolved and management still expects additional sales (“definitely a little more to do”), and the Austin structured loan’s Phase 2 is gated by unmet conditions with funding pushed to late Q1/early Q2 and net hold potentially reduced via further participation sales. Analysts also challenged the reduced acquisition/disposition guidance versus 2025; management confirmed it is mainly conservatism/avoidance of forced purchases rather than a clear demand collapse.
Growth Catalysts
- 22.7% growth in AFFO per common share driven by $142.1M of completed property acquisitions + commercial loan originations in Q4
- Record 2025 investments: $277.7M annual investment volume (8.6% full-year AFFO per common share growth)
- Commercial loan growth via originations: $102.3M of Q4 commitments at 13.5% weighted average initial coupon (incl. amendments and a $10M senior interest sale)
Business Development
- Acquisitions included investment-grade rated tenants Lowe's and Walmart; higher-yield investments included Germ-free labs headquarters/manufacturing facility
- Top tenants: Lowe's, Dick's Sporting Goods, Walmart in top 5 tenants collectively representing 29% of ABR
- Walgreens exposure reduction: Walgreens fell to #9 tenant with 5 remaining locations; management actively selling additional Walgreens now
- Commercial loans: Austin, TX luxury residential development (Phase I senior participation sold, with Phase II funding conditions)
- Guidance mentions use of equity/ATM and new unsecured credit facility to fund further loan/property activity (no named counterparties disclosed)
Financial Highlights
- Q4 revenue: $16.9M total (lease income $12.7M; interest income $4.0M); FFO/AFFO attributable to common: $0.54 per diluted share (+22.7% y/y)
- Full-year 2025 revenue: $60.5M total (lease income $48.7M; interest income $11.4M); full-year FFO $1.88, AFFO $1.89 per diluted share (+8.6% y/y)
- Property acquisitions: Q4 acquired 8 properties for ~$40M at weighted average initial cash cap rate 6.9%; full year 13 properties for $100.6M at 7.4% cap rate
- Property dispositions: Q4 included recycling; full year sold 9 noncore properties for $38.4M at 7.7% weighted average exit cap rate (portfolio disposition volume $72.8M total; 8% weighted average exit cap rate on income-producing properties)
- ABR quality shift: 51% of ABR generated from investment-grade rated tenants after 2025 activity; Walgreens reduced to 4% of ABR and down to #9 with 5 locations
- Commercial loans: Q4 originated 5 loans + amended 1 totaling $102.3M commitments at 13.5% weighted average initial coupon; full-year commercial loan originations $177M at 12% weighted average initial coupon (PIK included when applicable)
- Net commercial loan portfolio: $129.8M at year-end vs $48M at start of year; management targets loan allocation ~20% of total undepreciated asset value
- Capital markets / leverage: new unsecured credit facility recast; borrowings pricing improved by 10 to 15 bps
- Capital structure: ended year net debt / pro forma adjusted EBITDA at 6.7x vs 7.4x at start of year; liquidity $65.8M ($25.3M cash + $40.6M revolver capacity)
Capital Funding
- Nov. 12: issued $50M gross proceeds of 8% Series A preferred at $25/share; net proceeds $48.1M
- Series A preferred ATM: issued just over 116,000 shares at weighted average $24.92 for net proceeds ~$2.8M (late Q4 to early Q1 2026)
- Common ATM: issued just over 918,000 shares at weighted average $17.13 for net proceeds ~$15.5M (late Q4 to early Q1 2026)
- Total equity raised via ATM + Series A preferred ATM programs: $18.3M combined
- New unsecured credit facility: $250M revolving + $100M 3-year term loan + $100M 5-year term loan; used to repay prior revolver and term loans
- Liquidity expanded by potential in-place bank commitments: availability could expand by an additional $31.4M; total potential liquidity $97.3M at year-end
- No buyback disclosed in this transcript (investor comment references 'bought back a lot of stock last year')
Strategy & Ops
- 2025 execution: 'strategic barbell' acquisitions (investment-grade tenants plus higher-yield specialty assets like Germ-free labs)
- 2025 recycling plan: sold 9 noncore properties for $38.4M and completed full-year disposition volume of $72.8M
- Walgreens tenant workstream: active selling of additional Walgreens; management will 'take our time' to find right buyers and avoid forced sale
- Commercial loan strategy: originate high-yield coupons with quality sponsors; manage diversification via potential senior participation sales when needed
- 2026 underwriting/cadence: acquisition/disposition ranges reduced vs 2025 to maintain comfortable execution without 'forcing' purchases into commodity assets
Market Outlook
- 2026 initial guidance: FFO per diluted share $2.07 to $2.11; AFFO per diluted share $2.09 to $2.13
- 2026 investment volume assumption: $70M to $100M; disposition volume: $30M to $60M
- Guidance timing assumption: dispositions generally closing earlier than acquisitions
- Dividend: quarterly common dividend increased 5.3% to $0.30/share beginning Q1 2026; stated AFFO payout ratio ~56% of Q4 2025 AFFO
Risks & Headwinds
- Execution/valuation conservatism: acquisition/disposition guide down materially vs 2025; management framed as reducing pressure to buy less-attractive 'commodity assets' (not explicitly macro, but implies market selectivity)
- Tenant concentration risk management: Walgreens exposure still being reduced ("definitely a little more to do"; actively selling additional Walgreens) indicating ongoing tenant/credit overhang resolution
- Funding/loan-structure operational hurdle: Austin structured Phase 2 has 'conditions that are unmet'; funding expected around late Q1/early Q2 2026 (and likely involves additional senior participation sales, reducing net hold)
- Tax/rental accounting constraint affecting dividend coverage: loan portfolio has no depreciation/tax cover, driving higher taxable income and necessitating dividend level to support taxable income payout
Sentiment: MIXED
Note: This summary was synthesized by AI from the PINE Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.